Use of tranquilizers and sleeping pills among cancer patients is associated with a poorer quality of life
Use of tranquilizers and sleeping pills among cancer patients is associated with a poorer quality of life
复制标题
DOI：
10.1007/s11136-004-8745-1
复制
发表时间：
2004-12-01
影响因子：
3.5
通讯作者：
Peretz, T
中科院分区：
文献类型：
--
作者：
Paltiel, O;Marzec-Boguslawska, A;Peretz, T
目的：评估癌症患者安眠药/镇静剂 (SP/T) 使用与生活质量 (QOL) 之间的关联。患者和方法：对以色列三家医院的诊所、日间中心和住院部的肿瘤患者 (n = 909) 进行了关于上周 SP/T 使用情况的采访。使用欧洲癌症研究和治疗组织生活质量问卷-C30 (EORTC QLQ-C30) 测量的粗略和调整后的生活质量得分，对用户与非用户进行了比较。结果：234 名 (25.7%) 参与者自行报告了安眠药/镇定剂的使用情况，但很少记录在医疗图表中。与 SP/T 使用相关的因素包括女性（调整后比值比，OR：1.79；95% 置信区间，CI：1.22 - 2.62）、年龄（OR：4.6；95% CI：70 岁以上为 1.66 - 12.53）、出生地（东欧为 OR：1.97；95% CI：1.19 - 3.26）与以色列相比）、同时使用止痛药（OR：2.88；95% CI：1.97 - 4.20）和存在心血管疾病（OR：2.41；95% CI：1.48 - 3.91）。控制这些因素以及疾病状态后，用户在所有功能指标上的生活质量均较差（p < 0.001），而且总体生活质量有所提高。与未使用 SP/T 的患者相比，症状的严重程度，特别是疲劳、失眠、疼痛、呼吸困难和便秘 (p < 0.01) 结论：四分之一的癌症患者报告使用 SP/T 与生活质量显着较差有关，并且考虑到横断面设计，不可能进行因果推断，因为它可能会识别出生活质量较差和需求未得到满足的患者。
Purpose: To evaluate the association between sleeping pill/tranquilizer (SP/T) use and quality of life (QOL) among cancer patients. Patients and methods: Oncology patients ( n = 909) in three Israeli hospitals were interviewed in clinics, day centers and in-patient departments regarding SP/T use in the previous week. Crude and adjusted QOL scores, measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30), were compared in users vs. non-users. Results: Sleeping pill/tranquilizer use was self-reported by 234 (25.7%) participants, but rarely documented in medical charts. Factors associated with SP/T use were female gender ( adjusted Odds ratio, OR: 1.79; 95% Confidence interval, CI: 1.22 - 2.62, age ( OR: 4.6; 95% CI: 1.66 - 12.53 for age 70+), place of birth ( OR: 1.97; 95% CI: 1.19 - 3.26 for Eastern Europe compared with Israel), concomitant use of painkillers ( OR: 2.88; 95% CI: 1.97 - 4.20) and presence of cardiovascular disease ( OR: 2.41; 95% CI: 1.48 - 3.91). Controlling these factors as well as disease status, users had a poorer QOL on all functional scales ( p < 0.001) as well as global QOL. Furthermore, users reported increased severity of symptoms, especially fatigue, insomnia, pain, dyspnea and constipation ( p < 0.01), compared to non-users. Conclusions: Use of SP/T, reported by one fourth of cancer patients, was associated with substantially poorer QOL and increased severity of symptoms. Causal inference is not possible given the cross-sectional design. Periodic inquiry regarding use of these medications in the Oncology Clinic is recommended since it may identify patients with poor QOL and unmet needs.